BibbInstruments

BibbInstruments Current Assets

The Current Assets of BibbInstruments (BIBB.SL) as of Oct 20, 2026 is 2.30 M SEK.

Current Assets

2.30 MSEK

Last updated:

Current Assets of BibbInstruments is 2025 2.30 M SEK. Current Assets of BibbInstruments was 2024 0.00 SEK. It decreases by % higher compared to the previous year.

The BibbInstruments Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
8.06 M SEK
Jan 1, 2019
21.12 M SEK
Jan 1, 2020
22.69 M SEK
Jan 1, 2021
529,000.00 SEK
Jan 1, 2022
0.00 SEK
Jan 1, 2023
0.00 SEK
Jan 1, 2024
0.00 SEK
Jan 1, 2025
2.30 M SEK
The BibbInstruments Current Assets history
YEARCurrent AssetsYoY
2.30 MSEK—
0.00SEK—
0.00SEK—
0.00SEK-100.00%
529,000.00SEK-97.67%
22.69 MSEK+7.43%
21.12 MSEK+161.87%
8.06 MSEK-40.71%
13.60 MSEK+644.85%
1.83 MSEK+149.79%
731,000.00SEK+62.44%
450,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

Current Assets of BibbInstruments is 2.30 M SEK in 2025.

On Eulerpool you can find the complete historical development of Current Assets BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's BibbInstruments historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BibbInstruments

All Key Metrics — BibbInstruments